ASC-J9® suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L

2016 ◽  
Vol 379 (1) ◽  
pp. 154-160 ◽  
Author(s):  
Ronghao Wang ◽  
Wanying Lin ◽  
Changyi Lin ◽  
Lei Li ◽  
Yin Sun ◽  
...  
Tumor Biology ◽  
2017 ◽  
Vol 39 (5) ◽  
pp. 101042831769225 ◽  
Author(s):  
Jieping Hu ◽  
Gongxian Wang ◽  
Ting Sun

Androgen receptor plays a pivotal role in prostate cancer progression, and androgen deprivation therapy to intercept androgen receptor signal pathway is an indispensable treatment for most advanced prostate cancer patients to delay cancer progression. However, the emerging of castration-resistant prostate cancer reminds us the alteration of androgen receptor, which includes androgen receptor mutation, the formation of androgen receptor variants, and androgen receptor distribution in cancer cells. In this review, we introduce the process of androgen receptor and also its variants’ formation, translocation, and function alteration by protein modification or interaction with other pathways. We dissect the roles of androgen receptor in prostate cancer from molecular perspective to provide clues for battling prostate cancer, especially castration-resistant prostate cancer.


2021 ◽  
Vol 12 (24) ◽  
pp. 7349-7357
Author(s):  
Xuanrong Chen ◽  
Yi Shao ◽  
Wanqing Wei ◽  
Haishan Shen ◽  
Yang Li ◽  
...  

Oncotarget ◽  
2016 ◽  
Vol 7 (38) ◽  
pp. 61955-61969 ◽  
Author(s):  
Jingbo Qiao ◽  
Magdalena M. Grabowska ◽  
Ingrid S. Forestier-Roman ◽  
Janni Mirosevich ◽  
Thomas C. Case ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document